Drugs / CVXGA
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05736835 | Sep 2023 → Dec 2025 | COVID-19 | CyanVac LLC | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CVXGA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05736835 ↗ |
| Modality | Vaccine | “A Phase 2 Trial of the Immunogenicity and Safety of CVXGA Intranasal COVID Vaccine in Healthy Adults” NCT05736835 ↗ |
| Route | Intranasal | “The vaccine will be administered as a single intranasal dose as a spray.” NCT05736835 ↗ |